Qualifyze operates a compliance and quality-assurance platform for the pharmaceutical supply chain that combines a network of auditors with a database of suppliers and buyers to track adherence to standards such as GxP, ESG, ISO, and CAPA. The company manages a network of about 250 auditors and a database covering roughly 3,000 suppliers and 1,200 customers, and it uses technology to run analytics and surface manufacturing data. While technology powers its data management and analytics, the business model remains anchored around people — some auditors are employees and others are contracted, leading Qualifyze to build its own training and vetting processes. Qualifyze plans to use new funding to expand in the U.S. and to broaden its product set with additional analytics and AI capabilities. The Frankfurt-based startup is led by founder and CEO Dr. David Schneider, a former McKinsey consultant. Financially, Qualifyze announced a $54M Series B, bringing its total raised to $84M to date and a valuation the company says is "significantly higher" than the prior $100M post-money. Qualifyze offers a digital platform that manages audits end-to-end and captures audit data at scale to check supply-chain compliance for pharmaceutical firms. Founded in 2019 and based in Frankfurt, the company centralizes supplier-audit workflows and compliance data. Qualifyze says it serves more than 1,000 pharmaceutical clients and has been more than doubling every year while remaining profitable. Leadership positions the product as creating a new category of compliance data to increase drug safety and enable better allocation of investments into supply-chain compliance beyond GxP. The company plans to use new funding to accelerate growth and to further its mission of transforming supply-chain compliance in healthcare in a sustainable, data-driven manner.

Total raised

$66M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2024